Therefore, NFATc1 activity is an integrated component of tonic BCR signaling that is ‘hijacked’ from classical BCR signaling and should be considered as an alternative target for therapeutic intervention in BL cells. The gene discussed is NFATC1; the disease is Burkitt lymphoma.